To estimate the cost-effectiveness of using long-acting insulin analogues (LAIAs) compared to neutral protamine hagedorn (insulin NPH), in the treatment of diabetes mellitus (DM). This information may assist policy makers in making informed decisions on reimbursement of LAIAs. METHODS: An economic evaluation, from the perspective of a third-party provincial payer, was conducted using the Center for Outcomes Research (CORE) Diabetes Model (CDM). Clinical outcomes (e.g., A1c and hypoglycaemia) were derived from recent meta-analyses. Costs and utilities, both discounted at 5%, were obtained from published sources. Sensitivity analyses were performed to test the robustness of results. RESULTS: Type-1 DM (T1DM) -the incremental cost-utility ratio (ICUR) for insulin glargine relative to insulin NPH, was $87,932 per Quality Adjusted Life Year (QALY) gained (difference ( ) in cost, $3423; QALYs, 0.039). The ICUR for insulin detemir relative to insulin NPH, was $387,729 per QALY gained ( cost, $4,344; QALYs, 0.011). Type-2 DM (T2DM) -the ICUR for insulin glargine relative to insulin NPH, was $642,994 per QALY gained ( cost, $4,945; QALYs, 0.008). Insulin detemir was more costly ($6,521 per patient) and less effective ( 0.034 QALYs) than insulin NPH. Results were sensitive to variations of parameters in sensitivity analyses. CONCLUSIONS: Compared with insulin NPH, the use of LAIAs for the treatment of DM was associated with relatively high ICURs. The illness progression is faster when the patient also presents overweight or obesity. The objective of this study was to evaluate the clinical and economical impact of the use of metformine sibutramine versus metformine and acarbose as a treatment for weight loss in patients with DM-2 with obesity and/or overweight, in Mexico.
PDB23 ECONOMIC EVALUATION OF METFORMIN, METFORMIN + SIBUTRAMIN + OR ACARBOSE IN THE MANAGEMENT OF OVERWEIGHT AND OBESE DIABETES PATIENTS
The illness progression is faster when the patient also presents overweight or obesity. The objective of this study was to evaluate the clinical and economical impact of the use of metformine sibutramine versus metformine and acarbose as a treatment for weight loss in patients with DM-2 with obesity and/or overweight, in Mexico.
METHODS:
Cost-effectiveness analysis by decision tree of the pharmacological treatments for weight loss in patients with diabetes mellitus II from the health service provider perspective, considering a temporary horizon of 5 years. The considered effectiveness measure was the percentage of patients that reaches an IMC 25 without peritoneal dialysis. Costs were estimated using 2008 prices and are expressed in US dollars (exchange rate of 11.14 pesos/ 1 US dollar). RESULTS: According to the model, the effectiveness of each alternative was: metformine, 2.16%; acarbose, 2.16% and metformine sibutramine 50.18%. The treatement with metformine threw the lowest average cost per treated patient with DM-2 $9,486.3, followed by the treatments with metformine sibutramine y acarbose with a cost of $10,729.3 y $10,892.0 respectively. The average treatment cost-effectiveness in ascending order is: metformine sibutramine $21, 383.5, metformine $438,183.3; and acarbose $503,116.7 . The incremental cost of metformine sibutramine is $2589.1 and acarbose is an alternative dominated by metformine. CONCLUSIONS: Metformine sibutramine is a cost-effective alternative from the institutional perspective, in order to accomplish the weight loss in patients with diabetes mellitus type 2, with obesity or overweight in Mexico.
PDB24 COMPARISON OF GLUCOMETERS USED FOR SELF-MONITORING BLOOD GLUCOSE AMONG DIABETIC PATIENTS: A COST MINIMIZATION APPROACH.
Goyal R y , Sansgiry SS University of Houston, Houston, TX, USA OBJECTIVES: The purpose of this study was to compare glucometers used for selfmonitoring blood glucose in diabetic patients available at pharmacy stores by conducting a cost minimization analysis. METHODS: A prospective cross-sectional study design was used. Data was collected from 28 pharmacies, 4 each from local chain pharmacies namely CVS, Walgreens, Wal-Mart, Kroger, Randall's (Safeway), Target, and HEB in the Houston area. Glucometer use resource cost was calculated from patient's perspective and included the price of glucometers, lancet, and strips from each pharmacy store. The annual effective cost for glucometer use was calculated by considering number of tests performed by patients per day multiplied by the resource cost. A literature search from January 1996 to February 2007 was used to obtain utilization patterns for patients with type 1 and type 2 diabetes (T1D andT2D, respectively). Data was entered in an excel sheet and a cost minimization analysis was performed. RESULTS: Only 4 generic glucometers were identifi ed in the 28 pharmacies, while there were 10 branded glucometers in each. The price of glucometers, lancets, and strips differed by location and brand. HEB store brand glucometer, In ControlTM, was the most cost effective generic glucometer (annual cost, T1D $500.9, T2D $172.2). By selecting the appropriate generic glucometer, patients could save annually $125.9 to $148.94 (T1D patients) and $15.25 to $54.4 (T2D patients), respectively. The most cost effective brand name glucometer was by FreestyleTM obtained at Wal-Mart stores (annual cost, T1D $823.7, T2D $307.1). Depending upon the appropriately selected brand name glucometer, patients could save annually $168.3 to $627.6 (T1D patients) and $61.0 to $226.6 (T2D patients), respectively. CONCLU-SIONS: The cost to use glucometers varied by location and brand selected. Patients could save cost associated with testing their blood glucose by selecting the right glucometer that fi ts their budget.
PDB25 USE OF GENERALIZED LINEAR MODEL TO FIND THE RELATIONSHIP BETWEEN DIAGNOSIS AND THE COST OF DIABETIC OUTPATIENTS
Wang X g University of Louisville, Louisville, KY, USA OBJECTIVES: The purpose of this paper is to evaluate the relationship between the patient diagnoses and the Claims for total charges for outpatients with diabetes. We examine treatments in relationship to costs. METHODS: The dataset 'Outpatientbase-claim'of size 2,030,078 used for this paper is taken from the Chronic Condition Data Warehouse, which contains claim information for the year 2004. In this study, we use Summary Statistics, One-Way Frequencies, the Generalized Linear model in SAS Enterprise Guide 4.1 and Kernel Density Estimation. We utilize Filter and Query, Append Table, Join Table as well as Random Sampling to preprocess the data in order to analyze it. Although this dataset contains ICD9 codes for both diagnosis and procedures, Deductible and Coinsurance and so on, we mainly concentrate on patient diagnosis information and total charges. One-way frequency counts gave us the top 20 reasons for total charges and we use these 20 diagnoses to defi ne 0-1 indicator functions for regression. RESULTS: The results of the Summary Statistics show that the total charges for diagnosis are reduced considerably for payment. Kernel Density Estimation shows that the distribution of the total charges follows a Gamma distribution and most of the charges are under 3500 dollars. The Generalized Linear Model shows that only 15 of the newly-generated factors are signifi cant to the model, and these include Type II diabetes mellitus and chronic kidney disease. Renal failure is the most expensive condition to treat. CONCLUSIONS: Diagnosis has an important effect on the total charges of diabetic patients, but only 15 out of 20 diseases such as unspecifi ed essential hypertension and chronic kidney disease are statistically significant to the total charges. Chronic kidney disease has the most important effect on the total charges.
PDB26 RACE AND GENDER DIFFERENCES IN ECONOMIC BURDEN OF DIABETES HOSPITALIZATIONS IN TENNESSEE
White-Means S, Franklin BE, Brown LT University of Tennessee Health Science Center, Memphis, TN, USA OBJECTIVES: Tennessee residents face a heavy economic burden of diabetes. Costs of hospitalization and treatment were $2.9 billion in 2003. This study expands on previous work, analyzing race and gender differences in inpatient and outpatient hospital costs for patients with a primary diagnosis of diabetes in Tennessee. We hypothesize that Non-Hispanic Blacks, especially men, bear a disproportionately higher burden compared to Non-Hispanic Whites. METHODS: This study utilized inpatient and outpatient fi les from the 2003 Tennessee Hospital Discharge Data System. Chisquare and t-tests were performed to analyze signifi cant differences in key demographic and clinical factors among race-gender groups. Multivariate regression models were developed to estimate log inpatient and outpatient charges for all hospitalizations with a primary diagnosis of diabetes (ICD-9 code: 250). RESULTS: Analyses revealed signifi cant differences in comorbid presentations across race-gender groups and other factors contributing to charges. Overall, women were signifi cantly more likely to present with hypertension than men, although percentages for blacks were signifi cantly higher (all p 0.001). Ulcers were more prevalent in men versus women (all p 0.001), highest among white men (signifi cant only for outpatient events, p 0.001), and resulted in signifi cantly higher (48%, p 0.0001) inpatient charges. As predicted, hospital charges were highest among blacks, although black males had signifi cantly higher (20.2%, p 0.0001) mean inpatient charges and black females had signifi cantly higher (6.8%, p 0.0001) outpatient charges. CONCLUSIONS: To improve the quality of care in diabetes, it is critical to identify disparities in treatment. The analysis revealed that a signifi cantly higher percentage of men suffered ulcers, which significantly increased inpatient charges. As such, gender-targeted education may be warranted to reduce the incidence of diabetic ulcers. In addition, increased prevention efforts may be necessary in black communities to reduce avoidable hospitalizations.
PDB27 DIRECT COST OF DIABETES IN OPD CLINICS OF PAKISTAN
Khowaja LA j , Khuwaja AK Aga Khan University, Karachi, Sindh, Pakistan OBJECTIVES: Diabetes is a chronic and potentially disabling disease that represents an important public health and clinical concern. It is a growing epidemic and the cost of treating diabetes is largely increasing. This is fi rst of its kind of research study conducted in Pakistan. This study aimed to estimate the direct cost of Diabetes at outpatient clinics in Karachi, Pakistan, and to identify the high cost component of diabetes care. METHODS: Prevalence based Cost of Illness study was conducted in different out-patient clinics representing public, private and NGO/trustee based hospitals of Karachi, Pakistan in 2006. After taking informed consent, a pre-tested questionnaire was used to collect the data from 345 randomly selected persons with diabetes. RESULTS: The only annual mean direct cost tolerated by each person with diabetes was estimated to Pakistani rupees 11,580 (US$ 193). We found that increasing age, number of complications and longer duration of disease signifi cantly increases the
